Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Lenalidomide, Pomalidomide and CC-220 Resistant Multiple Myeloma: Confirmation of Role of CRBN/IRF4 Axis and Identification of Multiple Disruption Mechanisms

Yuan Xiao Zhu, PhD, Chang-Xin Shi, PhD, Laura Ann Bruins, BS, Xuewei Wang, PhD, Daniel Riggs, PhD, Brooke Porter, Jonathan Ahmann, BS, Esteban Braggio, PhD, P. Leif Bergsagel, MD, A. Keith Stewart, MBChB, MBA

Blood (2017) 130 (Supplement 1): 4369.

https://doi.org/10.1182/blood.V130.Suppl_1.4369.4369

Published: 2017

Journal Articles

PIKfyve Inhibitors for the Treatment of Multiple Myeloma

Cecilia Bonolo De Campos, PhD, Yuan Xiao Zhu, PhD, Chang-Xin Shi, PhD, Laura Ann Bruins, BS, Joachim L Petit, PhD, Alysia N Polito, BS, Meaghen E Sharik, BS, Caleb K Stein, MS, Gregory J Ahmann, BS, Ilsel D Lopez Armenta, BS, Nikolai Sepetov, PhD, Sergei Romanov, PhD, P. Leif Bergsagel, MD, Marta Chesi, PhD, Nathalie Meurice, PhD, A. Keith Stewart, MBChB, MBA

Blood (2017) 130 (Supplement 1): 4423.

https://doi.org/10.1182/blood.V130.Suppl_1.4423.4423

Published: 2017

Journal Articles

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial

A. Keith Stewart, MBChB, MBA, David Siegel, MD PhD, Heinz Ludwig, MD, Thierry Facon, MD, Hartmut Goldschmidt, MD, Andrzej J. Jakubowiak, MD, Jesus F. San Miguel, MD, Mihaela Obreja, Julie Blaedel, Meletios A. Dimopoulos

Blood (2017) 130 (Supplement 1): 743.

https://doi.org/10.1182/blood.V130.Suppl_1.743.743

Published: 2017

Journal Articles

IKZF1/3 and CRL4 CRBN E3 Ubiquitin Ligase Mutations Associate with IMiD Resistance in Relapsed Multiple Myeloma

Santiago Barrio Garcia, PhD, Matteo Da Via', MD, Andoni Garitano-Trojaola, PhD, Yanira Ruiz-Heredia, Max Bittrich, MD, ChangXin Shi, PhD, Yuan Zhu, Nicola Lehners, MD, Elias K Mai, MD, Marc S Raab, MD PhD, Pieter Sonneveld, MDPhD, Joaquín Martínez, Andreas Rosenwald, Esteban Braggio, PhD, Hermann Einsele, A. Keith Stewart, MBChB, MBA, K. Martin Kortüm, MD

Blood (2017) 130 (Supplement 1): 270.

https://doi.org/10.1182/blood.V130.Suppl_1.270.270

Published: 2017

Journal Articles

"Direct to Drug" Screening As a Route to Individualized Therapy in Multiple Myeloma

Nathalie Meurice, PhD, Joachim L Petit, PhD, Cecilia Bonolo De Campos, PhD, Alysia N Polito, BS, Ilsel D Lopez Armenta, BS, Gregory J Ahmann, BS, Laura Ann Bruins, BS, Joseph R Mikhael, MD FRCPC, MD, Craig B. Reeder, MD, Angela A Mayo, MS, PA-C, P. Leif Bergsagel, MD, Rafael Fonseca, MD, Nikolai Sepetov, PhD, Sergei Romanov, PhD, A. Keith Stewart, MBChB, MBA

Blood (2017) 130 (Supplement 1): 3080.

https://doi.org/10.1182/blood.V130.Suppl_1.3080.3080

Published: 2017

Journal Articles

Charting Venetoclax Sensitivity and Synergism Ex Vivo in Multiple Myeloma

Nathalie Meurice, PhD, Joachim L Petit, PhD, Jessica L Todsen, Cecilia Bonolo De Campos, PhD, Alysia N Polito, BS, Ilsel D Lopez Armenta, BS, Gregory J Ahmann, BS, A. Keith Stewart, MBChB, MBA

Blood (2017) 130 (Supplement 1): 3081.

https://doi.org/10.1182/blood.V130.Suppl_1.3081.3081

Published: 2017

Journal Articles

Role of MAX As a Tumor Suppressor Driver Gene in Multiple Myeloma

Santiago Barrio Garcia, PhD, Yanira Ruiz-Heredia, Matteo Da Via', MD, Miguel Gallardo, PhD, Andoni Garitano-Trojaola, PhD, Josip Zovko, MD, Marc S Raab, MD PhD, Pieter Sonneveld, MDPhD, Esteban Braggio, PhD, A. Keith Stewart, MBChB, MBA, Hermann Einsele, Joaquín Martínez, K. Martin Kortüm, MD

Blood (2017) 130 (Supplement 1): 4347.

https://doi.org/10.1182/blood.V130.Suppl_1.4347.4347

Published: 2017

Journal Articles

MYC Translocations Identified By Sequencing Panel in Smoldering Multiple Myeloma Strongly Predict for Rapid Progression to Multiple Myeloma

Niamh Keane, MB, MRCP, Caleb K Stein, MS, Daniel Angelov, MSc,MB, Shulan Tian, David Viswanatha, MD, Shaji K Kumar, MD, Angela Dispenzieri, MD, Veronica Gonzalez De La Calle, MD, Kristine Misund, PhD, Robert A Kyle, MD, Michael E O'Dwyer, MD, Rafael Fonseca, MD, A. Keith Stewart, MBChB, MBA, Esteban Braggio, PhD, Yan Asmann, PhD, S. Vincent Rajkumar, MD, P. Leif Bergsagel, MD

Blood (2017) 130 (Supplement 1): 393.

https://doi.org/10.1182/blood.V130.Suppl_1.393.393

Published: 2017

Journal Articles

MET-PET and NGS Targeted Sequencing Guides Precision Medicine in a CNS Relapsed MM Patient

Matteo Da Via', MD, Susanne Strifler, MD, Santiago Barrio Garcia, PhD, Andoni Garitano Trojaola, PhD, Eva Teufel, Silvia Nerreter, A. Keith Stewart, MBChB, MBA, Andreas Rosenwald, Anke Heidemeier, MD, Constantin Lapa, MD, Hermann Einsele, K. Martin Kortüm, MD

Blood (2017) 130 (Supplement 1): 5361.

https://doi.org/10.1182/blood.V130.Suppl_1.5361.5361

Published: 2017

Journal Articles

ADAR1-MediatedGLI1 Editing Promotes Malignant Self-Renewal in Multiple Myeloma

Leslie Crews, PhD, Elisa Lazzari, PhD, Phoebe Mondala, BS, Nathan Delos Santos, BS, Amber Miller, PhD BA, Gabriel Pineda, PhD, Qingfei Jiang, PhD, Heather Leu, BS, Shawn Ali, BA, Anusha Preethi Ganesan, MD PhD, Christina Wu, PhD, Caitlin L. Costello, MD, Mark D. Minden, MD PhD, Raffaella Chiaramonte, PhD, A. Keith Stewart, MBChB, MBA, Catriona Jamieson, MD PhD

Blood (2017) 130 (Supplement 1): 1204.

https://doi.org/10.1182/blood.V130.Suppl_1.1204.1204

Published: 2017

Journal Articles

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma

Martha Q. Lacy, MD, Suzanne R. Hayman, Morie A. Gertz, Jacob B. Allred, Sumithra J. Mandrekar, Angela Dispenzieri, Stephen R. Zeldenrust, Shaji Kumar, Philip R. Greipp, John A. Lust, Stephen J Russell, Francis Buadi, Robert A. Kyle, Peter Leif Bergsagel, MD, Rafael Fonseca, MD, Vivek Roy, MD, FACP, Joseph Mikhael, MD, A. Keith Stewart, MBChB, MBA, S. Vincent Rajkumar

Blood (2008) 112 (11): 866.

https://doi.org/10.1182/blood.V112.11.866.866

Published: 2008

Journal Articles

Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: The NCIC CTG MY.11 Trial

Darrell J White, MD, Nizar J Bahlis, MD, Deborah C Marcellus, MD, Andrew Belch, MD, A. Keith Stewart, MBChB, MBA, Christine Chen, MD, Michael J Kovacs, MD, David A Macdonald, MD, Donna E Reece, MD, Erica Harnett, MSc, Judy-Anne W Chapman, PhD, Ralph M Meyer, MD

Blood (2008) 112 (11): 2767.

https://doi.org/10.1182/blood.V112.11.2767.2767

Published: 2008

Journal Articles

Phase II Study of Melphalan, Prednisone and Lenalidomide Combination for Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation

Vivek Roy, MD, FACP, A. Keith Stewart, MBChB, MBA, P. Leif Bergsagel, MD, Angela Dispenzieri, M.D., Kristina Laumann, Jake Allred, Martha Q. Lacy, MD, Rafael Fonseca, MD, Craig B. Reeder, MD, Shaji Kumar, MD, Candido E. Rivera, MD, Morie A. Gertz, MD, Philip R. Greipp, MD, Francis K. Buadi, MD, Suzanne R. Hayman, MD, S. Vincent Rajkumar, MD

Blood (2008) 112 (11): 2769.

https://doi.org/10.1182/blood.V112.11.2769.2769

Published: 2008

NARROW

Lenalidomide, Pomalidomide and CC-220 Resistant Multiple Myeloma: Confirmation of Role of CRBN/IRF4 Axis and Identification of Multiple Disruption Mechanisms

PIKfyve Inhibitors for the Treatment of Multiple Myeloma

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial

IKZF1/3 and CRL4 CRBN E3 Ubiquitin Ligase Mutations Associate with IMiD Resistance in Relapsed Multiple Myeloma

"Direct to Drug" Screening As a Route to Individualized Therapy in Multiple Myeloma

Charting Venetoclax Sensitivity and Synergism Ex Vivo in Multiple Myeloma

Role of MAX As a Tumor Suppressor Driver Gene in Multiple Myeloma

MYC Translocations Identified By Sequencing Panel in Smoldering Multiple Myeloma Strongly Predict for Rapid Progression to Multiple Myeloma

MET-PET and NGS Targeted Sequencing Guides Precision Medicine in a CNS Relapsed MM Patient

ADAR1-MediatedGLI1 Editing Promotes Malignant Self-Renewal in Multiple Myeloma

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma

Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: The NCIC CTG MY.11 Trial

Phase II Study of Melphalan, Prednisone and Lenalidomide Combination for Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only